Open AccessMolecular Differences and Similarities between Alzheimer's Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis
Author(s) -
Chera L. Maarouf,
Tyler A. Kokjohn,
Charisse M. Whiteside,
MiMi P. Macias,
Walter M. Kalback,
Marwan N. Sabbagh,
Thomas G. Beach,
Robert Vassar,
Alex E. Roher
Publication year - 2013
Publication title -
biochemistry insights
Language(s) - English
Resource type - Journals
ISSN - 1178-6264
DOI - 10.4137/bci.s13025
Subject(s) - genetically modified mouse , presenilin , transgene , amyloid precursor protein , alzheimer's disease , neuroinflammation , apolipoprotein e , endogeny , amyloidosis , bace1 as , amyloid (mycology) , dementia , biology , endocrinology , microbiology and biotechnology , disease , pathology , medicine , biochemistry , gene
Transgenic (Tg) mouse models of Alzheimer's disease (AD) have been extensively used to study the pathophysiology of this dementia and to test the efficacy of drugs to treat AD. The 5XFAD Tg mouse, which contains two presenilin-1 and three amyloid precursor protein (APP) mutations, was designed to rapidly recapitulate a portion of the pathologic alterations present in human AD. APP and its proteolytic peptides, as well as apolipoprotein E and endogenous mouse tau, were investigated in the 5XFAD mice at 3 months, 6 months, and 9 months. AD and nondemented subjects were used as a frame of reference. APP, amyloid-beta (Aβ) peptides, APP C-terminal fragments (CT99, CT83, AICD), β-site APP-cleaving enzyme, and APLP1 substantially increased with age in the brains of 5XFAD mice. Endogenous mouse tau did not show age-related differences. The rapid synthesis of Aβ and its impact on neuronal loss and neuroinflammation make the 5XFAD mice a desirable paradigm to model AD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom